Xvivo Perfusion AB (XVIVO)

Stockholm
Currency in SEK
324.60
-3.00(-0.92%)
Closed·
XVIVO Scorecard
Full Analysis
Trading at a high earnings multiple
XVIVO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
321.20330.00
52 wk Range
238.20547.00
Key Statistics
Edit
Prev. Close
327.6
Open
327.4
Day's Range
321.2-330
52 wk Range
238.2-547
Volume
44.55K
Average Volume (3m)
127.08K
1-Year Change
-14.24%
Book Value / Share
66.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XVIVO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
448.50
Upside
+38.17%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth
Show more

Xvivo Perfusion AB Company Profile

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Employees
193
Market
Sweden

Xvivo Perfusion AB Earnings Call Summary for Q1/2025

  • XVIVO reports 14% organic growth in Q1 2025, with net sales of SEK 218 million; stock surges 8.65% despite slight revenue miss
  • Thoracic and abdominal sales grow 16% and 28% respectively; adjusted EBIT up 50% with 14% margin; gross margin stable at 73%
  • Company expects record year for XPS programs in 2025; production constraints to ease by Q4; new R&D center opening in Denver
  • Liver technology gains FDA breakthrough device designation; clinical trial targeting 215 patients across 20 clinics
  • CEO highlights high interest in XVIVO EVLP program; company projects EPS and revenue growth through FY2026
Last Updated: 2025-04-24, 09:42 a/m
Read Full Transcript

Compare XVIVO to Peers and Sector

Metrics to compare
XVIVO
Peers
Sector
Relationship
P/E Ratio
75.3x29.7x−0.5x
PEG Ratio
2.421.200.00
Price/Book
4.9x2.1x2.6x
Price / LTM Sales
12.1x2.2x2.9x
Upside (Analyst Target)
43.6%0.0%53.0%
Fair Value Upside
Unlock35.1%8.9%Unlock

Analyst Ratings

3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 448.50
(+38.17% Upside)

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
-0.39 / 0.9853
Revenue / Forecast
219.00M / 225.65M
EPS Revisions
Last 90 days

People Also Watch

222.00
MILDEF
-3.14%
150.00
YUBICO
-19.14%
625.50
CAMX
-0.79%
350.80
ADDTb
-1.13%

FAQ

What Is the Xvivo Perfusion AB (XVIVO) Stock Price Today?

The Xvivo Perfusion AB stock price today is 324.60

What Stock Exchange Does Xvivo Perfusion AB Trade On?

Xvivo Perfusion AB is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Xvivo Perfusion AB?

The stock symbol for Xvivo Perfusion AB is "XVIVO."

What Is the Xvivo Perfusion AB Market Cap?

As of today, Xvivo Perfusion AB market cap is 10.22B.

What Is Xvivo Perfusion AB's Earnings Per Share (TTM)?

The Xvivo Perfusion AB EPS (TTM) is 4.35.

When Is the Next Xvivo Perfusion AB Earnings Date?

Xvivo Perfusion AB will release its next earnings report on Jul 11, 2025.

From a Technical Analysis Perspective, Is XVIVO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.